How a patient association gave rise to a company

Last updated: June 24, 2024

A patient association in rare diseases is first and foremost families who all have one thing in common: they need a cure to be found and made available.

Discover how French company AtmosR worked with a patient association to tackle the need to find a cure for Ondine:

Subscribe to our newsletter

Leveraging the potential of Patient Reported Outcome (PRO) data to...

Gastrointestinal Tract Diseases Research: Moving Towards Patient-Centered Clinical Trials

Turning experience into evidence: PROs in IBD clinical research

BYOD on the rise

Strategies to promote BYOD adoption by clinical study sites

How Kayentis reduces the CO2 emissions of your eCOA projects...

About the author

Marc Chaperon

Estelle brings 20+ years of experience in pre-clinical and clinical research from Top 5 Pharma and Biotech firms. Leading projects across Phases 1 to 4 in diverse therapeutic areas, she offers deep insights into clinical science, operations, and regulatory intricacies. Appointed as Chief Medical Officer at Kayentis in May 2019.

Meet us at the following events

The critical importance of Patient Reported Outcomes (PROs) for Emerging Biopharma Companies – Webinar

July 9 • 11-12AM EDT / 4-5PM GMT / 5-6PM CET

In today’s competitive landscape, biotech and emerging biopharma companies (EBPs) must demonstrate the value of their innovations early and convincingly....